Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19626240 | 0.88 | PDE3B (0.40) | DGAT1 | |
| SCHEMBL19629422 | 0.87 | KCNH2 (0.32) | KCNH2FFAR1FEN1 | |
| SCHEMBL19626241 | 0.85 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL19626306 | 0.83 | CHUK (0.37) | DGAT1FFAR1FEN1 | |
| SCHEMBL19626255 | 0.82 | DGAT1 (0.36) | DGAT1KCNH2FEN1 | |
| SCHEMBL19626262 | 0.82 | DYRK1A (0.38) | DGAT1 | |
| SCHEMBL16608644 | 0.78 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL19629564 | 0.76 | PDE3B (0.37) | — | |
| SCHEMBL19626309 | 0.75 | CHUK (0.37) | DGAT1FFAR1 | |
| SCHEMBL19626264 | 0.74 | PDK1 (0.37) | DGAT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981962-B2 | Pyrazole derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K21 | DGAT1 2063/4885KCNH2 3509/4885FFAR1 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.